Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Austria Health Focus.
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual …
GlobeNewswire, Inc.
·
November 11, 2024
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and...
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire, Inc.
·
November 13, 2024
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of XOLREMDI® (mavorixafor) in WHIM underway;...
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
GlobeNewswire, Inc.
·
November 14, 2024
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR...
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
GlobeNewswire, Inc.
·
November 13, 2024
Mavorixafor durably and meaningfully elevated participants’ mean absolute neutrophil counts (ANC) Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal levels Phase 2 study results and new analysis...
Regional Workshop on TRIPS and contemporary policy issues concludes in Vienna
World Trade Organization
·
November 15, 2024
The workshop was hosted by the Joint Vienna Institute (JVI) and benefited from close collaboration with the secretariats of the World Intellectual Property Organization and the WTO, and contributions by the Medicines Patent Pool. The programme's...
QC Kinetix National Medical Director Dr. Mitchell Sheinkop is the Keynote Speaker at the International Conference on Stem Cells and Regenerative Medicine
GlobeNewswire, Inc.
·
November 11, 2024
Dr. Mitchell Sheinkop CHARLOTTE, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- QC Kinetix, a leader in the field of regenerative medicine, proudly announces that its National Medical Director, Dr. Mitchell Sheinkop, will advise physicians involved in...
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
GlobeNewswire, Inc.
·
October 31, 2024
NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire, Inc.
·
November 1, 2024
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on October 31, 2024, the company issued...
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
GlobeNewswire, Inc.
·
October 30, 2024
Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate eseba-vec in patients who are HPV16+ after treatment for...
Rise in nitrous oxide emissions endangers pathway to 1.5°C, the ozone layer, and human health
UN Environmental Program
·
November 12, 2024
Findings from the new Global Nitrous Oxide Assessment (N₂O) warns that without urgent action on rising N₂O emissions, there is no viable pathway to limiting global warming to 1.5°C, and provides tangible tools to reduce emissions by more than 40%...
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
GlobeNewswire, Inc.
·
October 24, 2024
BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter...
Personalized Medicine Market Revenue to Cross $ 746.01 Billion by 2032; Registering at a CAGR of 10.7% | VMR
EIN Presswire
·
October 4, 2024
Personalized Medicine Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2032 224 W 35TH ST STE 500, NY, UNITED STATES, October 4, 2024 /EINPresswire.com/ -- The Global Personalized Medicine Market Size was valued at USD...
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
GlobeNewswire, Inc.
·
August 25, 2025
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain,...
PlantX Life Inc. Announces Name Change and New Ticker Symbol as Part of Rebranding Effort to Focus on Wellness-Focused Technology and eCommerce
GlobeNewswire, Inc.
·
November 4, 2024
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("PlantX" or the "Company") is pleased to announce that it intends to proceed with a name change to "JIVA Technologies...
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
GlobeNewswire, Inc.
·
August 12, 2025
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at 90 days will be available...
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
GlobeNewswire, Inc.
·
October 8, 2024
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of Anna Truppel-Hartmann, M.D., as Chief Medical...
Regenerative Medicine Market is Targeting USD 154.05 Billion by 2033
GlobeNewswire, Inc.
·
October 1, 2024
Ottawa, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The global regenerative medicine market size was valued at USD 29.42 billion in 2023 and is predicted to surpass around USD 154.05 billion by 2033, according to Precedence Research. The regenerative...
FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication
U.S. Food and Drug Administration
·
August 25, 2025
AUDIENCE: Patient, Health Care Professional, Pharmacy, Cardiology, Neurology, Internal Medicine, Family Practice, Travel Clinics UPDATE: On August 22, 2025, the US FDA’s Center for Biologics Evaluation and Research (CBER) has suspended the...
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
GlobeNewswire, Inc.
·
October 8, 2024
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire, Inc.
·
October 1, 2024
BOSTON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on September 30, 2024, the company issued...